SELLAS Life Sciences Group, Inc. (SLS)
NASDAQ·Healthcare·Biotechnology
$11.56
-14.31%
Mkt Cap $2.60B
Analyst Ratings
No recent rating data.
Price Target (3 analysts)
$25.00
Range $25.00 – $25.00
Implied Upside
+116.3%
Consensus $25.00 vs current $11.56